Atrial Fibrillation and By-pass Surgery
Information source: Heart Center BH Tuzla
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Patients With Coronary Artery Disease Scheduled for by Pass Surgery
Intervention: Amiodarone tab 200 mg x 3 (Drug); rosuvastatin 20 mg tab x1 (Drug); beta blockers Bisoprolol in adjusted dose (Drug)
Phase: Phase 0
Status: Not yet recruiting
Sponsored by: Heart Center BH Tuzla Overall contact: Enes Osmanovic, Master's degree, Phone: +387 66 725 744, Email: osmanovic@bhsrce.ba
Summary
The aim of the study is to evaluate whether combined therapy with beta-blocker, amiodarone
and statine is better than beta-blocker alone for the prevention of atrial fibrillation
after coronary by-pass surgery.
Clinical Details
Official title: Pharmacologic Prophylaxis for Atrial Fibrillation Following Coronary By-Pass Surgery
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Primary outcome: atrial fibrillation
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- significant coronary disease, sinus rhythm
Exclusion Criteria:
- valvular disease, former by-pass surgery
Locations and Contacts
Enes Osmanovic, Master's degree, Phone: +387 66 725 744, Email: osmanovic@bhsrce.ba
Heart Center BH, Tuzla, TK 75000, Bosnia and Herzegovina; Not yet recruiting Enes Osmanović, Phone: +387 66 725 744, Email: osmanovic@bih.net.ba
Additional Information
Starting date: December 2013
Last updated: December 15, 2013
|